-
公开(公告)号：US20180094055A1
公开(公告)日：2018-04-05
申请号：US15787635
申请日：2017-10-18
Applicant: AMGEN INC.
Inventor： Cen XU , Agnes Eva HAMBURGER
IPC: C07K16/28
CPC classification number: C07K16/28 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
-
公开(公告)号：US20160251432A1
公开(公告)日：2016-09-01
申请号：US15158178
申请日：2016-05-18
Applicant: AMGEN INC.
Inventor： Cen XU , Agnes Eva HAMBURGER
IPC: C07K16/28
CPC classification number: C07K16/28 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
-
公开(公告)号：US20210017261A1
公开(公告)日：2021-01-21
申请号：US16919032
申请日：2020-07-01
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20160039939A1
公开(公告)日：2016-02-11
申请号：US14775995
申请日：2014-03-14
Applicant: AMGEN INC.
Inventor： Cen XU , Agnes Eva HAMBURGER
IPC: C07K16/28
CPC classification number: C07K16/28 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
Abstract translation: 提供了结合人PAC1的抗体及其抗原结合片段。 还提供了编码抗体及其抗原结合片段，载体和编码其的细胞的核酸。 抗体及其抗原结合片段可以抑制PAC1与PACAP的结合，并且可用于许多PAC1相关病症，包括治疗和/或预防头痛障碍，包括偏头痛和丛集性头痛。
-
公开(公告)号：US20210095016A1
公开(公告)日：2021-04-01
申请号：US17031674
申请日：2020-09-24
Applicant: AMGEN INC.
Inventor： Agnes E. HAMBURGER , Cen XU , Hong SUN , Yuan D. SHIH , Dohan WEERARATNE
Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
-
Patent Agency Ranking
公开(公告)号：US20200172614A1
公开(公告)日：2020-06-04
申请号：US16572271
申请日：2019-09-16
Applicant: AMGEN INC.
Inventor： Cen XU , Agnes Eva HAMBURGER
Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
-
公开(公告)号：US20150376286A1
公开(公告)日：2015-12-31
申请号：US14752493
申请日：2015-06-26
Applicant: AMGEN INC.
Inventor： Thomas C. BOONE , David W. BRANKOW , Colin V. GEGG, JR. , Shaw-Fen Sylvia HU , Chadwick T. KING , Hsieng Sen LU , Licheng SHI , Cen XU
IPC: C07K16/28
CPC classification number: C07K16/2869 , A61K39/395 , A61K39/39533 , A61K2039/505 , C07K2317/21 , C07K2317/32 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
Abstract translation: 提供了结合人CGRP受体（CGRP R）的抗原结合蛋白。 还提供编码抗原结合蛋白，载体和编码抗原结合蛋白的核酸的核酸。 抗原结合蛋白可以抑制CGRP R与CGRP的结合，并且可用于多种CGRP R相关疾病，包括治疗和/或预防偏头痛。
-
公开(公告)号：US20210179722A1
公开(公告)日：2021-06-17
申请号：US17111442
申请日：2020-12-03
Applicant: AMGEN INC.
Inventor： Thomas C. BOONE , David W. BRANKOW , Colin V. GEGG, JR. , Shaw-Fen Sylvia HU , Chadwick T. KING , Hsieng Sen LU , Licheng SHI , Cen XU
IPC: C07K16/28 , A61K39/395
Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
-
公开(公告)号：US20210047422A1
公开(公告)日：2021-02-18
申请号：US17005202
申请日：2020-08-27
Applicant: AMGEN INC.
Inventor： Gunasekaran KANNAN , Ling LIU , Edward J. BELOUSKI , Cen XU
Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
公开(公告)号：US20190218279A1
公开(公告)日：2019-07-18
申请号：US16246326
申请日：2019-01-11
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.016 seconds)
